CLDX Stock: Price, Earnings History and SEC Filings
Celldex Therapeutics, Inc. (CLDX) last traded at $30.10, up 0.70% on the latest session and down 7.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.94 against an analyst estimate of $-1.04, a beat of 9.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
CLDX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.94 | $-1.04 | +9.62% |
| Mar 2026 | May 7, 2026 | $-1.18 | $-1.10 | -7.27% |
| Dec 2025 | Feb 25, 2026 | $-1.22 | $-1.00 | -22.00% |
| Sep 2025 | Nov 10, 2025 | $-1.01 | $-0.88 | -14.77% |
CLDX beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How CLDX reacts to earnings
Across its last 8 earnings releases, CLDX moved 3.1% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | After close | +0.36% |
| 2026-05-07 | After close | +1.95% |
| 2026-02-25 | After close | -0.58% |
| 2025-11-10 | After close | +7.50% |
| 2025-08-07 | After close | -2.59% |
| 2025-05-08 | After close | -6.10% |
| 2025-02-27 | After close | +1.28% |
| 2024-11-06 | After close | -4.20% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
CLDX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $2M | -$259M | -$214M | -16748.0% | $-3.90 |
| 2024 | $7M | -$158M | -$160M | -2248.8% | $-2.45 |
| 2023 | $7M | -$141M | -$109M | -2054.8% | $-2.92 |
| 2022 | $2M | – | -$106M | – | $-2.40 |
| 2021 | $5M | – | -$62M | – | $-1.64 |
| 2020 | $7M | – | -$42M | – | $-2.02 |
| 2019 | $4M | – | -$47M | – | $-3.51 |
| 2018 | $10M | – | -$76M | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for CLDX
- 8-K · Sep 22, 2026Other events, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 15, 2026Officer or director change, Financial statements and exhibits
- 8-K · Jun 26, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 29, 2026
- 424B5 · Apr 2, 2026
- 8-K · Apr 2, 2026Material agreement, Other events, Financial statements and exhibits
Insider filing activity
CLDX insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
CLDX news
No recent headlines found. The live terminal has the full news feed.
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. (CLDX) is a US-listed public company on Nasdaq. The SEC classifies its business as In Vitro & In Vivo Diagnostic Substances. It is incorporated in DE. Its fiscal year ends in December.